Department of Health and Human Services' logo Department of Health and Human Services

Public Health Service
Food and Drug Administration
Center for Devices and Radiological Health


2098 Gaither Rd
Rockville, MD 20850

February 5, 1997

Augustine Lien
Vice President, Operations
Gynecare, Inc.
235 Constitution Dr
Menlo Park, CA 94025

Dear Mr Lien:

The US Food and Drug Administration (FDA) has reviewed Gynecare, Inc.'s promotional materials regarding the Uterine Balloon Therapy™ system. This product is a device as that term is defined in section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act). This device is part of an investigational clinical trial and does not yet have approved marketing clearance.

The Uterine Balloon Therapy system is being promoted on Gynecare, Inc.'s Internet home page These promotions represent the product as safe and effective for the treatment of menorrhagia, i.e., excessive menstrual bleeding. The promotional materials, copies of which are enclosed, include press releases and information distributed via the Internet. Some of the claims made about the unapproved device include, but are not limited to, the following:

These above-referenced materials establish that your firm is promoting the Uterine Balloon Therapy system for the treatment of menorrhagia despite the fact that the product has not received marketing clearance. Such promotion renders your Uterine Balloon Therapy system adulterated within section 501(i) of the Federal Food, Drug, and Cosmetic Act. Furthermore, Title 21 of the Code of Federal Regulations (21 CFR), section 812.7, prohibits the promotion and commercialization of an investigational device. A sponsor or investigator, or any person acting for or on their behalf, is prohibited from promoting or test marketing an investigational device until after the FDA has approved the device for commercial distribution. Furthermore, no claims can be made, either explicitly or implicitly, that the device is either safe or effective for the purposes for which it is being investigated or that the device is in any way superior to, or more cost-effective that any other device. Press releases and Internet websites may not be used as promotional tools or as an attempt to commercialize a product prior to approval or clearance.

Advertising for recruitment into an investigational device study should not use terms such as "new treatment, " "new medication," or "new therapy" without explaining that the test article is investigational. Phrases such as "The Uterine Balloon Therapy system is a new therapy which allows women who suffer from menorrhagia to lead a normal" life" and "our international clinical investigators have reported that this device … has a 95% success rate" as seen in the January 23, 1996, press release, implies that all study subjects will be receiving newly marketed products of proven worth.

Although the FDA does encourage the full exchange of scientific information concerning investigational devices, including the dissemination of scientific findings through scientific/medical publications or conferences, safety and efficacy conclusions and statements of a promotional nature are inappropriate.

This letter is not intended to be an all-inclusive list of deficiencies associated with the promotion of the Uterine Balloon Therapy system. It is your responsibility to ensure that materials distributed within the United States are in conformance with each requirement of the Act and other applicable Federal regulations.

Within fifteen (15) working days of receipt of this letter, please notify this office, in writing, of the specific actions you plan to take to correct the cited violations. You should include all steps being taken to address violative information currently in the marketplace and actions to prevent similar violations in the future.

Your response should be directed to the US Food and Drug Administration, Center for Devices and Radiological Health, Office of Compliance, Division of Bioresearch Monitoring, Program Enforcement Branch I, 2098 Gaither Rd, Rockville, MD 20850, Attention: Kevin M. Hopson. A copy of this letter has been sent to the US Food and Drug Administration, San Francisco District Office, 1431 Harbor Bay Pkwy, Alameda, CA 94502. We request that a copy of your response also be sent to that office.

Please direct all questions concerning this matter to Mr Hopson at 301-594-4720, extension 128.

Sincerely yours,
Charles W. Sedgwick for
Lillian J. Gill
Director, Office of Compliance


This page was posted on August 20, 2006.

Links to Recommended Companies

  • Compare drug prices and save money at verified online pharmacies.
  • Evaluates the quality of dietary supplement and herbal products.
  • Discount prices, huge inventory, and superb customer service.
  • OnlyMyEmail: Award-winning anti-spam services.
  • 10 Types: Website design, development, and hosting with superb technical support.